| Name | Title | Contact Details |
|---|
Southern Bancorp is a certified Community Development Financial Institution (CDFI) and B-Corp based in Arkadelphia, Arkansas. Established in 1986, it aims to strengthen underserved communities through financial services and development programs. The organization has grown significantly, now managing assets between $2.6 and $2.8 billion and serving around 65,000 customers in Arkansas and Mississippi. Southern Bancorp operates through three main entities: Southern Bancorp Bank, which provides traditional banking services; Southern Bancorp Community Partners, a nonprofit focused on financial education and support; and Southern Bancorp Incorporated, a holding company for strategic growth. The organization offers a range of services, including checking and savings accounts, loans, financial literacy workshops, and grants for community projects. With 56 locations and a commitment to equitable access, Southern Bancorp emphasizes long-term community impact, particularly in economically distressed areas.
We make pictures that sell your products.
We are an OEM manufacturer of linear actuators and lifting columns, located in the Greater Grand Rapids area! Our parents company, Jiecang Linear Motion Technology Co.,Ltd was established in 2000 in Xinchang, China. Due to their high standards, their products quickly became globally respected for use in medical and home care equipment. With a large customer base in the United States, they found it necessary to purchase a facility locally which happened in 2018.
Integrity is the nations leading distributor of life and health insurance, and provider of innovative solutions for wealth management and retirement planning.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.